Litcius/Paper detail

Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study

Seonggyu Byeon, Jung Yong Hong, Jeeyun Lee, Do‐Hyun Nam, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Seung Tae Kim

2020Targeted Oncology12 citationsDOI

Topics & Concepts

MedicineGefitinibResponse Evaluation Criteria in Solid TumorsInternal medicineRashOncologyClinical endpointChemotherapyRefractory (planetary science)Adverse effectSingle CenterCancerProgressive diseaseGastroenterologyClinical trialEpidermal growth factor receptorPhysicsAstrobiologyHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study | Litcius